Ruxolitinib in myelofibrosis: solutions for side effects and treatment failure

国际输血及血液学杂志 Pub Date : 2019-09-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.05.011

Xin Yan, Ze-feng Xu

{"title":"Ruxolitinib in myelofibrosis: solutions for side effects and treatment failure","authors":"Xin Yan, Ze-feng Xu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.011","DOIUrl":null,"url":null,"abstract":"Myelofibrosis(MF) is a type of myeloproliferative neoplasms which is difficult to be treated. With the discovery of V617F mutation in Janus kinase(JAK)2, JAK inhibitor provides a new treatment strategy for patients with myelofibrosis.Ruxolitinib is the first JAK1/2 inhibitor which approved by the Food and Drug Administration(FDA) for the treatment of patients with international prognostic scoring system(IPSS)intermediate-2 or high risk myelofibrosis. In clinical experiments, ruxolitinib demonstrates significant improvements in splenomegaly and disease-related constitutional symptoms, and prolongs patients′ overall survival. However, the side effects of the drug (hematocytopenia, infections and secondary neoplasms) and treatment failure of some patients has been observed in treatments. The adverse reaction and solutions of ruxlitinib; the definition, reason, high risk factors and prognosis of treatment failure; the salvage therapy after treatment failure will be discussed in this review. \n \n \nKey words: \nPrimary myelofibrosis; Janus kinases; Treatment failure; Salvage therapy; Adverse reaction; Ruxolitinib","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"429-434"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Myelofibrosis(MF) is a type of myeloproliferative neoplasms which is difficult to be treated. With the discovery of V617F mutation in Janus kinase(JAK)2, JAK inhibitor provides a new treatment strategy for patients with myelofibrosis.Ruxolitinib is the first JAK1/2 inhibitor which approved by the Food and Drug Administration(FDA) for the treatment of patients with international prognostic scoring system(IPSS)intermediate-2 or high risk myelofibrosis. In clinical experiments, ruxolitinib demonstrates significant improvements in splenomegaly and disease-related constitutional symptoms, and prolongs patients′ overall survival. However, the side effects of the drug (hematocytopenia, infections and secondary neoplasms) and treatment failure of some patients has been observed in treatments. The adverse reaction and solutions of ruxlitinib; the definition, reason, high risk factors and prognosis of treatment failure; the salvage therapy after treatment failure will be discussed in this review. Key words: Primary myelofibrosis; Janus kinases; Treatment failure; Salvage therapy; Adverse reaction; Ruxolitinib

查看原文本刊更多论文

鲁索利替尼治疗骨髓纤维化：副作用和治疗失败的解决方案

骨髓纤维化(MF)是一种较难治疗的骨髓增生性肿瘤。随着Janus kinase(JAK)2 V617F突变的发现，JAK抑制剂为骨髓纤维化患者提供了新的治疗策略。Ruxolitinib是美国食品和药物管理局(FDA)批准的首个JAK1/2抑制剂，用于治疗国际预后评分系统(IPSS)中2或高风险骨髓纤维化患者。在临床实验中，鲁索利替尼对脾肿大和疾病相关体质症状有显著改善，并延长患者的总生存期。然而，在治疗中观察到药物的副作用(血细胞减少、感染和继发性肿瘤)和一些患者的治疗失败。鲁西替尼的不良反应及解决方法治疗失败的定义、原因、高危因素及预后;本文将讨论治疗失败后的抢救治疗。关键词:原发性骨髓纤维化;Janus激酶;治疗失败;抢救治疗;不良反应;Ruxolitinib

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.